Pharmacokinetics of Pegylated Liposomal Doxorubicin

By A. Gabizon, H. Shmeeda, Y. Barenholz. Clinical Pharmacokinetics, 2003

1,213 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Liposomal Formulations in Clinical Use: An Updated Review (2017, background): “The overall lipid content of Doxil® is nearly 16 mg/mL and 2 mg/mL is the DOX concentration [9].”
Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds (2008, background): “The tissue distribution following intravenous injection of nanoparticulate carriers that involve encasement or encapsulation technology such as liposomes and various polymeric carriers have been extensively studied (Moghimi et al., 2001; Gabizon et al., 2003; Singh et al., 2006).”
The role of lipid components in lipid nanoparticles for vaccines and gene therapy (2022, positive): “By increasing circulation time, these well-anchored PEGlipids on the surface of Doxil -liposomes boost Dox accumulation at the tumor site [17] and decrease cardiotoxicity, as compared to free doxorubicin [68,69].”
Treating metastatic cancer with nanotechnology (2011, background): “; and changing the pharmacokinetic profile of a drug to increase its half-life at the disease sit”